To further extend the implications of our findings to the treatment of HPV-related cancers, we then picked out afatinib, a selective epidermal growth factor receptor (EGFR) inhibitor, due to its most positive sensitivity correlation with CDC42 according to analyses results from Cancer Therapeutics Response Portal (CTRP). Here, EGFR is linked to cancer.